Mabvax Therapeutics Holdings Inc. (MBVX) 2.1800

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mabvax Therapeutics Holdings Inc. (MBVX) 2.1800 $MBVX

MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts
ACCESSWIRE - Wed Jul 01, 1:16PM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
OPK: 16.55 (-0.01)

MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds
Marketwired - Wed Jul 01, 6:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company", a clinical stage immuno-oncology drug development company, announced today that it, collectively with OPKO Health, Inc. (NYSE: OPK), approved the release of $3.5 million in funds held in escrow from the $11.7 million financing the Company completed on April 10, 2015.
OPK: 16.55 (-0.01)

MabVax's HuMab 5B1 Toxicology Results In Context
Mayer Winkler - at Seeking Alpha - Thu Jun 11, 9:52AM CDT

OPK: 16.55 (-0.01)

MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT
PR Newswire - Thu May 28, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015.

MabVax Therapeutics Holdings, Inc. Provides Corporate Update and Reports First Quarter 2015 Financial Results
Marketwired - Fri May 15, 7:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, provided today a corporate update and reported financial results for the first quarter ended March 31, 2015.
OPK: 16.55 (-0.01)

MabVax Therapeutics' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing
PR Newswire - Tue May 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the final report on toxicology testing of its HuMab 5B1 antibody, which was completed by a leading independent contract research organization. The report detailed that the antibody, given in either a single dose or repeated doses, had no significant adverse findings even at the highest dosage levels tested. These results further validate the Company's decision to advance HuMab 5B1 into Phase 1 clinical trials before the end of 2015.

With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 28, 6:30AM CDT

OPK: 16.55 (-0.01), TEVA: 61.38 (-0.75)

The Real Value In MabVax May Be Partnerships Rather Than Pipeline
Mayer Winkler - at Seeking Alpha - Mon Apr 27, 9:47AM CDT

BLUE: 159.03 (+0.60), ZIOP: 11.17 (+0.69), BLCM: 19.58 (+0.74), OPK: 16.55 (-0.01), KITE: 64.36 (+1.05), CLLS: 35.72 (+1.27), JUNO: 52.05 (+1.72), ATRA: 54.17 (+0.76), NVS: 103.22 (+3.20), CELG: 118.84 (+1.97)

MabVax Therapeutics Analyst Brief by ARCE Research: Creating the Techniques to Fight Cancer in the Future Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Apr 17, 6:00AM CDT
MabVax Therapeutics Inc. (OTCQB: MBVX) based out of SAN DIEGO, CA is on the run to develop vaccines and antibodies based products to target specific forms of cancer. MabVax has an exclusive license to develop their vaccines at Memorial Sloan-Kettering Cancer Center (MSKCC). They then generate the monoclonal antibody with patients that have been treated with these licensed vaccines. MabVax is one of very few companies in the industry using this technique.

Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 2.95 (+0.11), RTTR: 4.29 (-0.05), APRI: 1.76 (+0.01)

MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You?
Greg Buch - at Seeking Alpha - Tue Apr 14, 6:52AM CDT

OPK: 16.55 (-0.01), JUNO: 52.05 (+1.72)

Opko Spots Another Overlooked Opportunity In MabVax Therapeutics
Wall Street Advisors - Seeking Alpha - Wed Apr 08, 10:13AM CDT
Opko Health (NYSE: OPK ) has a history of discerning overlooked assets in which to make strategic investments prior to value creation. Opko shareholders, in turn, get exposure to not only Opko's core assets, but also to a bevy of smaller, high growth...
OPK: 16.55 (-0.01), JUNO: 52.05 (+1.72)

MabVax Therapeutics Catches Eye of Billionaire Investor Dr. Phillip Frost and OPKO Health
Marketwired - Wed Apr 08, 7:30AM CDT
Investors at MabVax Therapeutics (OTCQB: MBVX) must feel like they're in just the right place at just the right time this week as news of billionaire Bio-Pharma Investor Dr. Phillip Frost, M.D., and his company OPKO Health (NYSE: OPK) have taken a strong interest in the clinical stage cancer immunotherapy company -- a $12 million interest. Dr. Frost is the CEO and Chairman of the Board at OPKO Health, and for those familiar with the good doctor, you already know that he and OPKO have a strong record of investing in biopharmaceutical firms.
OPK: 16.55 (-0.01)

MabVax Therapeutics elects Tom Varvaro to board
M2 - Wed Apr 08, 6:10AM CDT
Cancer immunotherapy company MabVax Therapeutics Holdings (OtherOTC:MBVX) reported on Tuesday that Tom Varvaro has been named as an independent director to its board of directors.

Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 16.55 (-0.01), PFE: 34.36 (+0.50), JUNO: 52.05 (+1.72), NVCN: 6.59 (-0.02)

MabVax secures private financing of almost $12M; shares up 28%
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 10:04AM CDT

OPK: 16.55 (-0.01)

MabVax Therapeutics Announces Closing of Financing
PR Newswire - Mon Apr 06, 8:36AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company", a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement" led by OPKO Health, Inc. (NYSE: OPK) and Dr. Phillip Frost, CEO and Chairman of OPKO Health.
OPK: 16.55 (-0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Surge in Gold Prices Reflects Political and Economic Tensions

Updated Category News Views 283

Gold Prices Reach New Heights Amid Political Turmoil Gold prices have reached unprecedented levels recently, reflecting a surge in safe-haven demand driven by rising political uncertainties in key regions like the U.S. and Japan. As concerns about potential economic instability grow, this precious metal has emerged as a popular choice for investors looking to protect...

Continue Reading
BlackSky Secures Navy Contract to Enhance Satellite Imaging

Updated Category News Views 222

Alright, here’s the scoop: BlackSky Technology Inc. just bagged a major contract with the U.S. Navy, and it’s all about beefing up their Gen-3 imaging satellites. Now, why does this matter? This initiative is a piece of the broader Project Overmatch—a military strategy designed to supercharge the Joint All Domain Command and Control (JADC2) mission. What’s at...

Continue Reading
Discover the Innovative FINGER GRIP for Enhanced Sports Performance

Updated Category News Views 217

Enhancing Sports with the Innovative FINGER GRIP In the dynamic world of sports, having the right equipment can make all the difference. An inventive mind from Pittsburgh has introduced an innovative product, the FINGER GRIP, aimed at elevating performance in games like pickleball and tennis. This new grip is revolutionizing how athletes interact with their paddles and...

Continue Reading
Updated Voting Shares of AB Volvo: Significant Changes

Updated Category News Views 215

Changes in AB Volvo's Voting Shares AB Volvo has recently undergone an important transformation affecting its voting shares. The conversion of 175,000 Series A shares into Series B shares is a key development for the company. This conversion stems from a provision accepted at the 2011 Annual General Meeting, allowing Series A shareholders to switch their shares to Series...

Continue Reading
Warner Bros. Discovery's Q4: Strong Revenue Growth & Future Plans

Updated Category News Views 324

Warner Bros. Discovery Reports Impressive Q4 Results In a recent financial assessment, Warner Bros. Discovery, Inc (NASDAQ: WBD) unveiled its latest quarterly performance, showcasing a fiscal fourth-quarter revenue of $10.03 billion. Although this represented a slight 1% ex-FX decline compared to the previous year, it was just shy of analysts' expectations of $10.19...

Continue Reading